Adaptive Biotechnologies (ADPT) CCO Bobulsky sells 11,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 11,000 shares of Common Stock at $18.00 per share. After the transaction, she directly holds 416,775 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025.

Insider Trade Summary 10b5-1

Net Seller: 11,000 shares ($198,000)

Net Sell 1 txn

Insider BOBULSKY SUSAN

Role Chief Commercial Officer, MRD

Sold 11,000 shs ($198K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,000	$18.00	$198K

Holdings After Transaction: Common Stock — 416,775 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 11,000 shares Sale price: $18.00 per share Shares held after transaction: 416,775 shares +1 more

4 metrics

Shares sold 11,000 shares Open-market sale of Common Stock on June 4, 2026

Sale price $18.00 per share Price for the 11,000 shares of Common Stock sold

Shares held after transaction 416,775 shares Direct ownership after reported sale

Rule 10b5-1 plan adoption date December 16, 2025 Trading plan governing the reported sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBULSKY SUSAN

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer, MRD

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		S(1)		11,000	D	$18	416,775	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

	Susan Bobulsky by Kyle Piskel, Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Adaptive Biotechnologies (ADPT) insider Susan Bobulsky report on this Form 4?

Susan Bobulsky reported an open-market sale of 11,000 shares of Adaptive Biotechnologies Common Stock at $18.00 per share. Following this transaction, she directly holds 416,775 shares, according to the Form 4 insider trading disclosure.

What is the role of Susan Bobulsky at Adaptive Biotechnologies (ADPT)?

Susan Bobulsky serves as Chief Commercial Officer, MRD at Adaptive Biotechnologies. Her Form 4 filing reflects personal trading activity in the company’s Common Stock, providing transparency into transactions by a senior executive of the business.

At what price did the ADPT insider shares sell in the reported transaction?

The reported transaction shows shares of Adaptive Biotechnologies Common Stock sold at $18.00 per share. This price applies to the 11,000 shares involved in the open-market sale disclosed in the Form 4 filing for Susan Bobulsky.

How many Adaptive Biotechnologies (ADPT) shares does Susan Bobulsky hold after the sale?

After selling 11,000 shares, Susan Bobulsky directly holds 416,775 shares of Adaptive Biotechnologies Common Stock. This post-transaction ownership figure is reported in the Form 4 and reflects her remaining direct equity position in the company.

Was the ADPT insider sale by Susan Bobulsky made under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 16, 2025. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary timing decisions.